<DOC>
	<DOCNO>NCT00551044</DOCNO>
	<brief_summary>The aim study comprehensively monitor effect nonsteroidal antiandrogen patient require hormone manipulation prostate cancer</brief_summary>
	<brief_title>Bicalutamide Monotherapy Has Significant Quality Life Benefits Men With Advanced Prostate Cancer</brief_title>
	<detailed_description>Androgen deprivation therapy mainstay treatment advanced prostate cancer . There increase tendency towards earlier treatment hormone manipulation . However , luteinizing hormone-releasing agonist decrease serum testosterone castrate level within two week commencement.They associate loss libido , loss muscle bulk accelerate bone loss . Osteoporotic patient high risk fragility fracture . An alternative nonsteroidal antiandrogen bicalutamide block testosterone receptor level , allow androgen deprivation prostate without reduce circulating level testosterone . This preserve desire effect androgen-sensitive tissue , result advantageous side effect profile . The aim study closely monitor osteoporotic patient commence bicalutamide period 12 month . Patients review dedicated prostate cancer clinic every 3 month . Patients question regard adverse event . Renal liver function test , prostate specific antigen , testosterone , estradiol bone turnover marker measure 3 monthly . Measurement height , weight , body mass index , quadriceps strength use dynamometry , skeletal mass use arm anthropometry ( mid-arm circumference triceps skinfold thickness ) , carry 3 monthly . Quality life issue assess 3 monthly use Rand 36-Item Health Survey ( SF36 ) University California-Los Angeles Prostate Cancer Index ( UCLAPCI ) . Patients undergo bone densitometry forearm baseline 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Osteoporotic patient ( T score â‰¤ 2.5 ) advance prostate cancer require hormone manipulation , due biochemical relapse follow either radical prostatectomy , radiotherapy , brachytherapy , biochemical progression initially observe prostate cancer . Severe hepatic insufficiency , bilirubin reference range Previous systemic therapy prostate cancer Radiotherapy within 6 month Previous invasive malignancy Any severe concomitant disease .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>prostatic neoplasm</keyword>
	<keyword>bicalutamide</keyword>
	<keyword>quality life</keyword>
	<keyword>osteoporosis</keyword>
</DOC>